Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Accumulated Expenses (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Accumulated Expenses for 6 consecutive years, with $13.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 35.75% to $13.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.6 million, a 35.75% decrease, with the full-year FY2025 number at $13.6 million, down 35.75% from a year prior.
  • Accumulated Expenses was $13.6 million for Q4 2025 at Relay Therapeutics, down from $25.1 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $33.2 million in Q3 2024 to a low of $8.9 million in Q1 2021.
  • A 5-year average of $21.8 million and a median of $22.2 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 135.36% in 2021, then crashed 35.75% in 2025.
  • Relay Therapeutics' Accumulated Expenses stood at $13.6 million in 2021, then skyrocketed by 67.46% to $22.7 million in 2022, then plummeted by 34.41% to $14.9 million in 2023, then skyrocketed by 42.62% to $21.2 million in 2024, then plummeted by 35.75% to $13.6 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Accumulated Expenses are $13.6 million (Q4 2025), $25.1 million (Q3 2025), and $23.2 million (Q2 2025).